George R. Siber, M.D.

Dr. Siber serves on ILiAD’s Scientific Advisory Board and is an infectious disease trained physician with more than 35 years of experience in developing vaccines and antibody products. He is currently Chief Scientific Officer of ClearPath Vaccines, a vaccine development company which is developing a global vaccine portfolio for Astellas Pharma. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (now Pfizer). While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines, including Prevnar, the first pneumococcal conjugate vaccine which has had a very significant impact on mortality globally and which has achieved multibillion dollar revenues; Acel-Imune, an acellular pertussis vaccine; Rotashield, the first vaccine against rotavirus diarrhea vaccine, Meningitec, the first meningococcal meningitis conjugate vaccine and FluMist, a nasal influenza vaccine. Prior to Wyeth, Dr. Siber was Director and responsible head of the Massachusetts Public Health Biologic Laboratories and also a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber led the research and manufacturing of multiple vaccines and immune globulins including Respigam, the first human immune globulin against respiratory syncytial virus. Dr. Siber currently serves on the Boards of Directors of Genocea and Affinivax, and is a member of the Board of Trustees of the International Vaccine Institute in Seoul, Korea. Dr. Siber is currently a member of the SAB of CureVac, Veritas Gene and Vaxess, and serves as a consultant to the Gates Foundation, PATH, the Wellcome Trust and the EC. Dr. Siber is currently an Adjunct Professor of Medicine at Johns Hopkins Medical School. Dr Siber is the recipient of the 2016 Albert E Sabin Gold Medal for outstanding contributions to vaccinology. Dr. Siber holds an MD degree from McGill University in Canada, received post-doctoral training in Internal Medicine at Rush-Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and training in Infectious Diseases and Vaccinology at Children’s Hospital and Beth Israel Hospital, Harvard Medical School, Boston.

Copyright 2013-2024 ILiAD Biotechnologies